C3 and systemic lupus erythematosus: The treatment ameliorated SLE, as several parameters of the disease activity of SLE were improved, including significant reduction of patients with fever and arthritis, restoration of serum levels of C3 and CH50, and decrease of SLEDAI scores (from 19.5 to 4.0 in P-LN, from 14.5 to 4.0 in non-LN), compared with those before treatment.